<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335761</url>
  </required_header>
  <id_info>
    <org_study_id>MDT17030</org_study_id>
    <nct_id>NCT03335761</nct_id>
  </id_info>
  <brief_title>InterStim® Amplitude Study</brief_title>
  <official_title>InterStim® Amplitude Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedtronicNeuro</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedtronicNeuro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This feasibility study will explore the effects of three different InterStim amplitude&#xD;
      settings on overactive bladder symptoms (OAB).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, multicenter, single-blinded study to explore the efficacy&#xD;
      and quality of life (QoL) of 3 different amplitude settings.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Actual">November 6, 2019</completion_date>
  <primary_completion_date type="Actual">November 6, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Urinary Urge Incontinence (UUI) Episodes Per Day From Baseline to 12 Weeks.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Symptoms related to OAB were evaluated using paper voiding diaries. Subjects were trained to complete the urinary voiding diaries for 3-days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in QoL Using ICIQ-OAB QOL From Baseline to 12 Weeks.</measure>
    <time_frame>12 weeks</time_frame>
    <description>International Consultation on Incontinence Modular Questionnaire - Overactive Bladder Symptoms Quality of Life Questionnaire The questionnaire consists of 4 subscales and a single item on urinary symptom interference.&#xD;
The four subscales of Concern (7 items), Coping (8 items), Sleep (5 items), and Social (5 items) are measured on a scale from 0-100 using a range percentile transformation on the summed value from individual listed items. The Health-Related Quality of Life (HRQL) score is a calculated score with a range from 0 to 100 using a range percentile transformation on the summed value from the subscales. Subjects were asked a urinary symptom interference question. &quot;Interference&quot; was measured on a scale from 0-10.&#xD;
A positive change in Concern, Coping, Sleep, Social, and HRQL indicates improvement in Quality of Life; a negative change in Interference indicates improvement in Quality of Life.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Urinary Urge Incontinence</condition>
  <arm_group>
    <arm_group_label>Amplitude Setting #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>InterStim Therapy will be set to amplitude parameter #1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amplitude Setting #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>InterStim Therapy will be set to amplitude parameter #2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amplitude Setting #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>InterStim Therapy will be set to amplitude parameter #3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InterStim Therapy</intervention_name>
    <description>Device Programming</description>
    <arm_group_label>Amplitude Setting #1</arm_group_label>
    <arm_group_label>Amplitude Setting #2</arm_group_label>
    <arm_group_label>Amplitude Setting #3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Primary diagnosis of urinary urge incontinence (UUI) as demonstrated on a 3-day&#xD;
             baseline voiding diary demonstrating at least 3 UUI episodes&#xD;
&#xD;
          2. Female subjects 18 years of age or older&#xD;
&#xD;
          3. Candidate for InterStim Lead Placement&#xD;
&#xD;
          4. Willing and able to accurately complete voiding diaries, questionnaires, attend&#xD;
             visits, and comply with the study protocol (which includes maintenance of InterStim II&#xD;
             programming settings over the course of the study)&#xD;
&#xD;
          5. Willing and able to provide signed and dated informed consent&#xD;
&#xD;
          6. Willing to maintain current regimen (dosage and frequency) of any overactive bladder&#xD;
             (OAB) medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have neurological conditions such as multiple sclerosis, clinically significant&#xD;
             peripheral neuropathy or spinal cord injury&#xD;
&#xD;
          2. History of diabetes unless the diabetes is well-controlled through diet and/or&#xD;
             medications&#xD;
&#xD;
          3. Symptomatic urinary tract infection (UTI)&#xD;
&#xD;
          4. Have primary stress incontinence or mixed incontinence where the stress component&#xD;
             overrides the urge component&#xD;
&#xD;
          5. Treatment of urinary symptoms with botulinum toxin in the past 9 months or any plan to&#xD;
             have botulinum toxin treatment during the study&#xD;
&#xD;
          6. Implanted with a neurostimulator, pacemaker, or defibrillator&#xD;
&#xD;
          7. Have knowledge of planned MRIs, diathermy, microwave exposure, high output ultrasonic&#xD;
             exposure, or radio frequency (RF) energy exposure not included within the scanning&#xD;
             conditions provided with the MRI Guidelines for InterStim Therapy&#xD;
&#xD;
          8. Women who are pregnant or planning to become pregnant&#xD;
&#xD;
          9. Characteristics indicating a poor understanding of the study or characteristics that&#xD;
             indicate the subject may have poor compliance with the study protocol requirements.&#xD;
&#xD;
         10. Currently enrolled or planning to enroll in a potentially confounding clinical study&#xD;
             during the course of the study (co-enrollment in concurrent studies is only allowed&#xD;
             when documented pre-approval is obtained from the Medtronic study manager (or&#xD;
             designee).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Academic Urology &amp; Urogynecology of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Coast Institute for Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinellas Urology</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Urology Partners</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Urology Fridley</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Urology Woodbury</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult Pediatric Urology and Urogynecology</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Research &amp; Consulting</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urology Partners</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Hamilton County Hospital Authority d/b/a Erlanger Health System</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Research Institute - Aurora West Allis Women's Pavilion</name>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <zip>53227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Campus Gasthuisberg - Department Urology</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Urology Associates, Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpitaux de Rouen - Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust - University College Hospital</name>
      <address>
        <city>London</city>
        <zip>W1G 8PH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <results_first_submitted>November 3, 2020</results_first_submitted>
  <results_first_submitted_qc>December 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2021</results_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary</keyword>
  <keyword>Incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03335761/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03335761/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Out of 97 subjects enrolled in the study, 48 were randomized, 46 were implanted with a neurostimulator device, and 43 completed their 12 week follow-up visit before exiting the study. Nineteen were randomized to 50% of sensory threshold, 14 were randomized to 80% of sensory threshold, and 15 were randomized to sensory threshold.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Amplitude Setting #1 = 50% Sensory Threshold</title>
          <description>InterStim Therapy will be set to amplitude parameter #1 (50% Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
        </group>
        <group group_id="P2">
          <title>Amplitude Setting #2 = 80% Sensory Threshold</title>
          <description>InterStim Therapy will be set to amplitude parameter #2 (80% Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
        </group>
        <group group_id="P3">
          <title>Amplitude Setting #3 = Sensory Threshold</title>
          <description>InterStim Therapy will be set to amplitude parameter #3 (Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Implanted With a Neurostimulator Device</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This summarizes demographics for subjects in the Randomized Subject Set.</population>
      <group_list>
        <group group_id="B1">
          <title>Amplitude Setting #1 = 50% Sensory Threshold</title>
          <description>InterStim Therapy will be set to amplitude parameter #1 (50% Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
        </group>
        <group group_id="B2">
          <title>Amplitude Setting #2 = 80% Sensory Threshold</title>
          <description>InterStim Therapy will be set to amplitude parameter #2 (80% Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
        </group>
        <group group_id="B3">
          <title>Amplitude Setting #3 = Sensory Threshold</title>
          <description>InterStim Therapy will be set to amplitude parameter #3 (Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="16"/>
                    <measurement group_id="B2" value="57.9" spread="16.1"/>
                    <measurement group_id="B3" value="56.7" spread="14.9"/>
                    <measurement group_id="B4" value="60" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.0" spread="5.7"/>
                    <measurement group_id="B2" value="36.3" spread="11.2"/>
                    <measurement group_id="B3" value="33.1" spread="6.4"/>
                    <measurement group_id="B4" value="32.8" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Urinary Urge Incontinence (UUI) Episodes Per Day From Baseline to 12 Weeks.</title>
        <description>Symptoms related to OAB were evaluated using paper voiding diaries. Subjects were trained to complete the urinary voiding diaries for 3-days.</description>
        <time_frame>12 weeks</time_frame>
        <population>Complete Case Subject Set</population>
        <group_list>
          <group group_id="O1">
            <title>Amplitude Setting #1 = 50% Sensory Threshold</title>
            <description>InterStim Therapy will be set to amplitude parameter #1 (50% Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
          </group>
          <group group_id="O2">
            <title>Amplitude Setting #2 = 80% Sensory Threshold</title>
            <description>InterStim Therapy will be set to amplitude parameter #2 (80% Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
          </group>
          <group group_id="O3">
            <title>Amplitude Setting #3 = Sensory Threshold</title>
            <description>InterStim Therapy will be set to amplitude parameter #3 (Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Urge Incontinence (UUI) Episodes Per Day From Baseline to 12 Weeks.</title>
          <description>Symptoms related to OAB were evaluated using paper voiding diaries. Subjects were trained to complete the urinary voiding diaries for 3-days.</description>
          <population>Complete Case Subject Set</population>
          <units>UUI episodes/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UUI episodes per day at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="2.9"/>
                    <measurement group_id="O2" value="5.3" spread="3.1"/>
                    <measurement group_id="O3" value="5.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UUI episodes per day at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="2.6"/>
                    <measurement group_id="O2" value="2.4" spread="3.0"/>
                    <measurement group_id="O3" value="1.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in UUI episodes per day from baseline to 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="2.6"/>
                    <measurement group_id="O2" value="-2.9" spread="2.9"/>
                    <measurement group_id="O3" value="-3.6" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in QoL Using ICIQ-OAB QOL From Baseline to 12 Weeks.</title>
        <description>International Consultation on Incontinence Modular Questionnaire - Overactive Bladder Symptoms Quality of Life Questionnaire The questionnaire consists of 4 subscales and a single item on urinary symptom interference.&#xD;
The four subscales of Concern (7 items), Coping (8 items), Sleep (5 items), and Social (5 items) are measured on a scale from 0-100 using a range percentile transformation on the summed value from individual listed items. The Health-Related Quality of Life (HRQL) score is a calculated score with a range from 0 to 100 using a range percentile transformation on the summed value from the subscales. Subjects were asked a urinary symptom interference question. &quot;Interference&quot; was measured on a scale from 0-10.&#xD;
A positive change in Concern, Coping, Sleep, Social, and HRQL indicates improvement in Quality of Life; a negative change in Interference indicates improvement in Quality of Life.</description>
        <time_frame>12 weeks</time_frame>
        <population>Complete Case Subject Set</population>
        <group_list>
          <group group_id="O1">
            <title>Amplitude Setting #1 = 50% Sensory Threshold</title>
            <description>InterStim Therapy will be set to amplitude parameter #1 (50% Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
          </group>
          <group group_id="O2">
            <title>Amplitude Setting #2 = 80% Sensory Threshold</title>
            <description>InterStim Therapy will be set to amplitude parameter #2 (80% Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
          </group>
          <group group_id="O3">
            <title>Amplitude Setting #3 = Sensory Threshold</title>
            <description>InterStim Therapy will be set to amplitude parameter #3 (Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
          </group>
        </group_list>
        <measure>
          <title>Change in QoL Using ICIQ-OAB QOL From Baseline to 12 Weeks.</title>
          <description>International Consultation on Incontinence Modular Questionnaire - Overactive Bladder Symptoms Quality of Life Questionnaire The questionnaire consists of 4 subscales and a single item on urinary symptom interference.&#xD;
The four subscales of Concern (7 items), Coping (8 items), Sleep (5 items), and Social (5 items) are measured on a scale from 0-100 using a range percentile transformation on the summed value from individual listed items. The Health-Related Quality of Life (HRQL) score is a calculated score with a range from 0 to 100 using a range percentile transformation on the summed value from the subscales. Subjects were asked a urinary symptom interference question. &quot;Interference&quot; was measured on a scale from 0-10.&#xD;
A positive change in Concern, Coping, Sleep, Social, and HRQL indicates improvement in Quality of Life; a negative change in Interference indicates improvement in Quality of Life.</description>
          <population>Complete Case Subject Set</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Coping from baseline to 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" spread="30.4"/>
                    <measurement group_id="O2" value="41.0" spread="26.3"/>
                    <measurement group_id="O3" value="39.4" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Concern from baseline to 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" spread="28.9"/>
                    <measurement group_id="O2" value="50.3" spread="17"/>
                    <measurement group_id="O3" value="49.9" spread="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Sleep from baseline to 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" spread="26.6"/>
                    <measurement group_id="O2" value="37.8" spread="22.7"/>
                    <measurement group_id="O3" value="32.0" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Social from baseline to 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="25.0"/>
                    <measurement group_id="O2" value="28.6" spread="17"/>
                    <measurement group_id="O3" value="20.6" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HRQL from baseline to 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" spread="24.4"/>
                    <measurement group_id="O2" value="40.5" spread="16.7"/>
                    <measurement group_id="O3" value="37.1" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Interference from baseline to 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="3.3"/>
                    <measurement group_id="O2" value="-4.7" spread="3.0"/>
                    <measurement group_id="O3" value="-4.7" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Post-Neurostimulator device implant to 12 weeks follow-up visit</time_frame>
      <desc>Serious, device related, procedure related, and/or therapy related adverse events are considered reportable for this study</desc>
      <group_list>
        <group group_id="E1">
          <title>Amplitude Setting #1 = 50% Sensory Threshold</title>
          <description>InterStim Therapy will be set to amplitude parameter #1 (50% Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
        </group>
        <group group_id="E2">
          <title>Amplitude Setting #2 = 80% Sensory Threshold</title>
          <description>InterStim Therapy will be set to amplitude parameter #2 (80% Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
        </group>
        <group group_id="E3">
          <title>Amplitude Setting #3 = Sensory Threshold</title>
          <description>InterStim Therapy will be set to amplitude parameter #3 (Sensory Threshold)&#xD;
InterStim Therapy: Device Programming</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Medical device site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mylène Champs (Sr Clinical Research Specialist)</name_or_title>
      <organization>Medtronic</organization>
      <phone>+17635261627</phone>
      <email>mylene.champs@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

